Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenue	$ 94,000	$ 206,000
Costs and expenses:
Cost of revenue	175,000	240,000
Research and development	7,412,000	4,454,000
General and administrative	1,647,000	1,221,000
Total costs and expenses	9,234,000	5,915,000
Loss from operations	(9,140,000)	(5,709,000)
Change in fair value of derivative liabilities		308,000
Interest expense		(267,000)
Loss on extinguishment of related party convertible promissory note		(2,180,000)
Other income (expense), net	73,000	(14,000)
Loss before provision for income taxes	(9,067,000)	(7,862,000)
Provision for income taxes	0	0
Net loss	(9,067,000)	(7,862,000)
Net loss attributable to noncontrolling interests	0	0
Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (9,067,000)	$ (7,862,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (0.79)	$ (7.13)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	11,475,749	1,102,571